A B S T R A C T
Background: Iron depletion is a known consequence of chronic kidney disease (CKD), but there is contradicting epidemiological evidence on whether iron itself affects kidney function and whether its effect is protective or detrimental in the general population. While epidemiological studies tend to be affected by confounding and reverse causation, Mendelian randomization (MR) can provide unconfounded estimates of causal effects by using genes as instruments. Methods: We performed an MR study of the effect of serum iron levels on estimated glomerular filtration rate (eGFR), using genetic variants known to be associated with iron. MR estimates of the effect of iron on eGFR were derived based on the association of each variant with iron and eGFR from two large genome-wide meta-analyses on 48 978 and 74 354 individuals. We performed a similar MR analysis for ferritin, which measures iron stored in the body, using variants associated with ferritin. Results: A combined MR estimate across all variants showed a 1.3% increase in eGFR per standard deviation increase in iron (95% confidence interval 0.4-2.1%; P ¼ 0.004). The results for ferritin were consistent with those for iron. Secondary MR analyses of the effects of iron and ferritin on CKD did not show significant associations but had very low statistical power.
Conclusions: Our study suggests a protective effect of iron on kidney function in the general population. Further research is required to confirm this causal association, investigate it in study populations at higher risk of CKD and explore its underlying mechanism of action.
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I N T R O D U C T I O N
It is well known that chronic kidney disease (CKD) can cause iron depletion, and iron supplementation is widely used to prevent and treat anaemia in CKD patients [1, 2] . What is not known is whether iron can influence kidney function and disease in the general population, and it is unclear whether altered iron levels could also be a cause, rather than a consequence, of kidney disease. The deleterious effects of iron accumulation in tissues under iron-overload conditions is well recognized, and experimental models of both acute kidney injury and CKD have suggested that iron could be nephrotoxic even in the absence of systemic overload, possibly through the formation of free radicals [3] [4] [5] [6] . However, studies in rats have shown that dietary iron elimination can cause tissue damage through oxidative stress and mitochondrial damage [7, 8] . Cellular iron Nephrol Dial Transplant (2017) 32: 273-278 doi: 10.1093/ndt/gfw215 Advance Access publication 2 June 2016 homeostasis plays an important role in mitochondrial biogenesis, and iron deprived cells show downregulation of mitochondrial protein levels and oxidative capacity [9] .
Assessing the effects of iron on kidney function in humans using observational data is very challenging because of the difficulty in disentangling causal from spurious effects due to confounding and reverse causation. On the other hand, randomized clinical trials investigating the effect of iron supplementation on kidney function in healthy individuals would be difficult to justify. In situations like this, Mendelian randomization (MR) is being increasingly used to provide estimates of causal effects of modifiable risk factors (e.g. biomarkers) on disease traits. MR is an instrumental variable approach based on the use of genes as 'proxies' (instruments) for the biomarker: genetic variants known to be associated with altered levels of the biomarker are investigated for their effect on the clinical endpoint [10, 11] . Being carried from birth, genes cannot be influenced by changes in the clinical endpoint (no reverse causation) or lifestyle and environmental predictors (no classical confounding). Moreover, the MR approach estimates the lifetime effect of the risk factor on the clinical endpoint, as opposed to the effect at a certain point in life estimated by classical observational studies.
The rapidly accumulating evidence on genetic associations for biomarkers (and other risk factors) and disease traits explains the increasing interest in the use of MR to distinguish between spurious and causal associations. As with any other instrumental variable approach, MR suffers from limited statistical power [10] , but the availability of very large genetic datasets currently ensures adequate power to investigate the causal effects on disease of many risk factors. However, the validity of MR heavily depends on the validity of the instruments chosen, which makes selection of the genetic variants the most important step of an MR study. A key aspect is the 'strength' of the instrument (the genetic variant), defined as a function of both the magnitude of the genetic effect on the risk factor and the precision with which it is estimated; the use of weak instruments can introduce bias (weak-instrument bias) [12] . Given the modest genetic effects typical of common variants, adequate instrument strength is usually achieved through large sample sizes for the gene-risk factor association. Another fundamental aspect is the absence of pleiotropy, which means that the instrument influences the disease trait only through the risk factor considered and not through any other pathway. This is the most challenging assumption in MR, and its violation can produce biased MR estimates [10, 11] .
In this study we used MR to investigate the lifetime causal effect of serum iron levels on kidney function in the general population. Kidney function was evaluated based on the estimated glomerular filtration rate (eGFR) from serum creatinine using the four-parameter Modification of Diet in Renal Disease (MDRD) equation. We used genetic data from the largest genome-wide association (GWA) consortia for iron markers (GIS consortium) [13] and eGFR (CKDGen consortium) [14] . As instruments, we selected all variants found associated with serum iron levels and replicated in the GIS consortium, with the exception of one variant that we excluded because of possible pleiotropic effects on the kidney. To investigate whether findings for the effect of circulating iron levels on kidney function could also be observed for iron stored in the body, we performed a similar MR analysis for the effect of serum ferritin levels on eGFR, again using all genetic variants associated with ferritin and replicated in the GIS consortium. Finally, we repeated the MR analyses to estimate the effects of both iron and ferritin on the risk of CKD, defined as eGFR <60 mL/min/ 1.73 m 2 .
M E T H O D S

Selection of genetic variants and investigation of pleiotropy
We considered as instruments for the MR analyses all genetic variants reaching genome-wide significance (P < 5 Â 10
À8
) in the combined discovery and replication analysis of the GIS consortium on serum iron and ferritin, based on a total sample size of 48 978 individuals from 18 studies, which represents the largest GWA meta-analysis conducted so far on these phenotypes [13] .
For the MR analysis of the effect of iron on eGFR, five variants were considered: rs855791 (also known as V736A) in the transmembrane protease 6 (TMPRSS6) gene, rs1800562 (C282Y) and rs1799945 (H63D) in the hemochromatosis (HFE) gene, rs8177240 in the transferrin (TF) gene and rs7385804 in the transferrin receptor 2 (TFR2) gene. All variants are independent, that is, they are not in linkage disequilibrium (LD), including the two variants in HFE (LD r 2 ¼ 0.01) located in genomic regions coding for functionally distinct protein domains [15, 16] . These variants were associated with serum iron levels at P-values ranging from 10 À20 to 10
À139
. Three of them, rs855791, rs1800562 and rs1799945, were already known to affect serum iron levels [17, 18] .
For the MR analysis of the effect of ferritin on eGFR, six variants were considered, three of which were the same as for iron, TMPRSS6 rs855791, HFE rs1800562 and HFE rs1799945; the other three included a variant located between the WD Repeat Domain 75 (WDR75) and the Solute Carrier Family 40 (IronRegulated Transporter) Member 1 (SLC40A1) genes, rs744653; a variant in the ABO Blood Group (ABO) gene, rs651007; and a variant in the Testis Expressed 14 (TEX14) gene, rs411988. These six variants were associated with ferritin with P-values ranging from 10 À8 to 10
À38
. For all variants for iron and ferritin, we investigated the possible presence of pleiotropy both a priori based on biological knowledge and a posteriori based on statistical evidence. For the biological assessment, we performed a literature search to identify evidence on the effects of the genes in which the selected variants are annotated. In cases where the variants were acting as cis and/or trans expression quantitative trait loci (eQTLs), we also included in our investigation any additional gene showing differential expression. For the latter task, we used several freely available online tools, including GTEx (http://www.gtexportal. org/home/), the Blood eQTL database [19] and ENCODE project data at University of California, Santa Cruz Genome Browser (https://genome.ucsc.edu/ENCODE/). For the statistical assessment of possible unknown pleiotropic effects, or other 274 F. Del Greco M et al.
factors invalidating the MR assumption that any effect of the variant on eGFR is mediated by iron (or ferritin), we investigated the heterogeneity of MR estimates across instruments using the heterogeneity Q test (p-het) and the I 2 index, as we have previously described [20] .
Estimates for the gene-iron and gene-ferritin associations
The effects of the genetic variants on serum iron and ferritin were based on the GIS GWA meta-analysis of 48 978 individuals from the 18 studies. The analyses were adjusted for sex, age and study-specific covariates such as genetic principal components to control for population structure [13] .
Because estimates of genetic effects from the discovery stage can be affected by an upward bias, referred to as 'winner's curse' [21] , sensitivity analyses were performed using estimates for the effects of the variants on iron and ferritin from the replication sample only, which included data on 24 986 individuals from eight studies.
The strength of each instrument was evaluated using the F statistic, which is a function of the magnitude and precision of the genetic effect on the biomarker:
, where R 2 is the proportion of the variance of iron (or ferritin) explained by the genetic variant and N is the sample size of the gene-iron (or gene-ferritin) association [22] . The R 2 values were estimated using the formula 2
where EAF is the effect allele frequency and b is the estimated genetic effect on iron (or ferritin) [23] .
Estimates for the gene-eGFR association
The effects of the variants on eGFR were obtained from the CKDGen consortium meta-analysis, which included 74 354 individuals from 26 population-based studies [14] . The genetic effects refer to per-allele effects on log-transformed eGFR. eGFR was estimated based on serum creatinine using the MDRD formula [24] . Similar to iron and ferritin, the genetic association analyses for eGFR were adjusted for sex, age and study-specific covariates such as genetic principal components to adjust for population structure [14] . Effects of the same variants on CKD, defined as eGFR <60 mL/min/1.73 m 2 and corresponding to CKD stages 3-5, were obtained from the same meta-analysis, which included 6271 CKD cases [14] .
Mendelian randomization analysis
MR estimates of the effect of iron on eGFR were derived for each instrument separately, using the Wald-type estimator, which is the ratio between the genetic effect on log(eGFR) (gene-eGFR association) and the genetic effect on serum iron levels (gene-iron association). The standard error of each MR estimate was derived using the delta method [25] . The MR estimates were then combined using fixed-effect inverse-variance weighted meta-analysis. The same approach was used for the MR analysis of ferritin.
We also performed MR analyses to assess the effect of both iron and ferritin on the risk of CKD. However, these were only considered to be secondary analyses because of the very low statistical power. The power calculation was performed using the online calculator for MR studies available at https://cnsgenomics.shinyapps.io/mRnd/ [26] . All analyses were performed using Stata 13 (StataCorp, College Station, TX, USA).
R E S U L T S
The studies included in the GIS consortium for iron and ferritin had a mean age ranging from 14 (SD 5) to 68 (SD 13) years. Detailed information on study-specific iron and ferritin levels by sex are reported in the supplement of Benyamin et al. [13] , available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC42 15164/bin/NIHMS619770-supplement-1.pdf (p. 18). The studies included in the CKDGen consortium for eGFR and CKD were characterized by mean age ranging from 46 (SD 16) to 76 (SD 5) years. The mean eGFR ranged from 96.5 (SD 39.9) to 71.2 (SD 14.8) mL/min/1.73 m 2 , and the median prevalence of CKD cases was 7.9%, ranging from 3.1 to 25.0% across studies. Detailed study-specific information can be found in the Supplementary data, Of the five variants associated with iron at a genome-wide significance level in the combined discovery and replication analysis of the GIS consortium (TMPRSS6 rs855791, HFE rs1800562 and rf1799945, TF rs8177240, TFR2 rs7385804), the rs7385804 variant was excluded because of likely pleiotropic effects of TFR2 on kidney function independent from iron. This variant is reported as a cis-eQTL in blood and is associated with expression of the SLC12A9 and EPHB4 genes. In animal studies, these two genes have been shown to increase blood pressure, thus potentially affecting GFR (SLC12A9) [27, 28] , and to promote survival of podocytes in glomerular disease models (EPHB4) [29] . For the other four instruments, we found no evidence of pleiotropic effects based on current biological knowledge from the published literature and bioinformatics databases. Detailed findings for all variants are reported in the Supplementary data.
All four genetic variants represent very strong instruments, with F statistics ranging between 98 and 1000 (Table 1) ; these values are much higher than the conventional threshold of 10 used as a rule of thumb to distinguish between strong and weak instruments [30] . The four variants jointly explain 4% of the variance of iron levels in the GIS consortium [13] . Table 1 reports the estimates of their per-allele effect on SD units of iron from the combined discovery and replication analyses of the GIS consortium (48 978 individuals) and the per-allele effect on (log)eGFR from the discovery analysis of the CKDGen consortium (74 354 individuals) [14] . The MR estimate obtained from each variant and reported in Table 1 represents the effect of iron on log(eGFR), expressed as the change in log(eGFR) per SD unit increase in iron. The pooled MR estimate across the four variants ( Figure 1A estimate was driven by the two HFE variants, which showed highly consistent estimates; the MR estimates from the TMPRSS6 and TF variants showed no effect, although the latter had very large CIs, thus carrying little information. The sensitivity analysis using estimates only from the replication stage of the GIS consortium showed the same pooled MR estimate as the main analysis, a 1.3% increase in eGFR per SD increase in iron (95% CI 0.4-2.3%; P ¼ 0.007). All of the six variants considered for ferritin (TMPRSS6 rs855791, HFE rs1800562 and rs1799945, WDR75-SLC40A1 rs744653, ABO rs651007, TEX14 rs411988) were used as instruments in our MR analysis because we found no evidence of pleiotropic effects for any of them (Supplementary data). The estimates for the gene-ferritin association are reported in Table 2 , and they refer to per-allele effects on SD units of log 10 -transformed ferritin from the combined discovery and replication analysis in the GIS consortium. Similar to iron, the MR analysis showed a protective and statistically significant effect of ferritin on log(eGFR) ( Figure 1B) . The pooled MR estimate of the effect of an SD unit of log 10 (ferritin) on log(eGFR) was 0. 021 (95% CI 0.004-0.037; P ¼ 0.014). As for iron, there was evidence of heterogeneity across MR estimates (I 2 ¼ 71%; p-het ¼ 0.004). The results were the same in the sensitivity analysis performed using estimates from the replication stage only, with a pooled MR estimate of 0.023 (95% CI 0.004-0.041; P ¼ 0.018).
The results of our secondary analyses evaluating the effects of iron and ferritin on the risk of CKD were not statistically significant (Supplementary data, Tables S1 and S2). The odds ratio (OR) of CKD for an SD unit increase in iron was 1.01 (95% CI 0.87-1.16) (Supplementary data, Figure S1a ). For ferritin, the OR was 0.91 (95% CI 0.70-1.20) per SD unit increase in log 10 (-ferritin) (Supplementary data, Figure S1b ). Such nonsignificant results are not surprising given the low statistical power of these analyses. Despite the high number of prevalent cases included in the analyses, the power of the MR approach to detect a 10% decrease in CKD risk per unit SD increase in iron at a significance level of 5% was only 28%.
D I S C U S S I O N
Our study suggests a causal protective effect of circulating and stored iron on kidney function. These findings contrast with the observation that iron overload, resulting in hemosiderosis, can damage the kidney [31] through generation of reactive oxygen species in proximal tubular cells [3] and modulation of immune effector function of circulating monocytes [32] . They are, however, in line with evidence showing that inadequate levels of iron can cause oxidative stress and, in particular, mitochondrial dysfunction due to mitochondrial DNA damage associated with oxidative stress [7, 8] . Both iron depletion and iron excess might therefore be detrimental to tissues. Increased cellular iron availability might be necessary for mitochondrial proteins, which contain iron/sulphur clusters as a cofactor. However, if accumulated above normal cellular levels, mitochondrial superoxide produced by the respiratory chain could result in the release of toxic soluble iron from iron/sulphur clusters, which is an additional source of reactive oxygen species generation [33] .
Although very promising, our findings require confirmation. Despite our efforts to minimize the possibility of bias, and in particular to exclude pleiotropic effects, we did observe high between-instrument heterogeneity. Our thorough review of Knowledge of the biological function of genes is rapidly evolving but still largely incomplete, as is knowledge of the effects of a variant on the expression of other genes (eQTL) within specific tissues, such as the kidney. Moreover, pleiotropy is not the only possible explanation for the observed between-instrument heterogeneity, which could be due to other causes of departures from the assumptions underlying MR, including canalization, gene-environment interactions and population stratification [10] . A follow-up of the findings of our study in experimental and functional models would provide conclusive evidence and an understanding of the underlying mechanism of action of iron on kidney function.
It should also be noted that although highly statistically significant, the effects of iron and ferritin on eGFR reported in our study are of limited magnitude. Further MR studies covering populations with wider ranges of eGFR and serum iron levels could better assess the dose-response relationship of the effect of iron on kidney function and the possible presence of threshold effects, e.g. a level of iron above which its effect on eGFR becomes minimal or even detrimental. This will require studies based on sample sizes even larger than those used here, or based on study populations with a larger number of CKD cases and of subjects with altered iron levels. In general, although Mendelian randomization is a valuable tool for assessing causality when randomized clinical trials are not an option, the magnitude of the causal effect estimate that it provides may not correspond to the effect of an intervention modifying the exposure of interest [34] . Our Mendelian randomization study estimates the lifetime causal effect of serum iron levels on kidney function in the general population, an effect that could be very different from the effect, for example, of acute changes in iron levels induced by iron supplementation in a population at risk of developing CKD.
A possible limitation of our study is that data available from the CKDGen, which is the largest GWA consortium on kidney function, were based on eGFR using the MDRD-4 equation. A different method has recently been proposed, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which has shown superior accuracy in subjects' classification. Although the use of GWA data for eGFR based on the CKD-EPI equation could provide more accurate MR estimates, we would not expect differences in the direction of the effect, given the high degree of concordance between MDRD-4 and CKD-EPI eGFR [35] .
Confirmation of our findings has practical importance at both the clinical and public health levels. At a clinical level, establishing the exact role of iron metabolism in the regulation of kidney function is crucial given that iron currently tends to be considered detrimental, with some authors suggesting the use of iron chelators for the prevention and treatment of kidney disease [36] . Iron metabolism in the kidney is characterized by complex processes, and there may be a narrow window for 'optimal iron levels', which could explain the apparently contradictory findings on whether iron is protective or detrimental for kidney function. Conclusive evidence on a protective role of iron in kidney function could also impact population health policies, because both absolute and functional iron deficiencies are the most common nutritional deficiency in the world, particularly in women and children, and simple iron supplementation could easily address the issue [37] .
In conclusion, our findings suggest a beneficial effect of higher circulating and stored iron levels on kidney function in the general population. Further research is required to confirm this causal association, investigate it in study populations at higher risk of CKD and explore its underlying mechanism of action.
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